<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305626</url>
  </required_header>
  <id_info>
    <org_study_id>STUD-192206</org_study_id>
    <nct_id>NCT04305626</nct_id>
  </id_info>
  <brief_title>Coated Mongolian Aneurysm Treatment Study 1</brief_title>
  <acronym>COMATS 1</acronym>
  <official_title>Clinical Evaluation of the p64 MW HPC and the p48 MW HPC Flow Diverters in an Observational Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phenox GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phenox GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW
      HPC Flow Modulation Device under Dual Antiplatelet Medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Observational Registry With p64 MW HPC and p48 MW HPC in Unruptured Anterior
      Circulation Aneurysms Under Dual Antiplatelet Medication.

      Purpose: To assess safety and effectiveness of p64 MW HPC or p48 MW HPC under Dual
      Antiplatelet Medication in consecutive patients with unruptured anterior circulation
      aneurysms.

      Follow-up intervals: Independent follow-ups (after 3 to 6 months and after 12 months and
      after 24 months) according to site specific standard.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>Within 30 days after the intervention</time_frame>
    <description>Occurence of ischemic or hemorrhagic stroke. Incidence of ischemic or hemorrhagic stroke in the territory supplied by the treated artery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>Within the first 12 months after the intervention</time_frame>
    <description>Occurence of all adverse events and serious adverse events, related directly or indirectly to the intervention, the used device or the required medication.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Efficacy endpoint</measure>
    <time_frame>12 months after the intervention</time_frame>
    <description>Complete occlusion or the neck remnant of the target aneurysm(s), identified by DSA (Digital subtraction angiography).</description>
  </other_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <condition>Aneurysm</condition>
  <condition>Vascular Diseases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular treatment of intracranial aneurysms</intervention_name>
    <description>Endovascular treatment of intracranial aneurysms with flow diversion.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population for this Observational Registry are patients with unruptured
        intracranial aneurysms suitable for flow diversion on operators' discretion. Patients can
        be included in the Observational Registry if they meet all of the inclusion and none of the
        exclusion criteria and have provided written informed consent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one unruptured sidewall aneurysm in the anterior circulation

          -  No implant (e.g., stent) in the target vessel segment

          -  Age &gt;18 years and &lt;80 years

          -  Not pregnant and in women of childbearing age, on oral contraception for two years
             following the procedure

          -  No participation in another trial

          -  No concomitant disease limiting the life expectancy to &lt;2 years

          -  No allergy to non-ionic contrast medium or to ASA and P2Y12 receptor antagonists

          -  No other neurovascular disorder in the same vascular territory requiring treatment in
             the foreseeable future

          -  Ability and willingness to comply with the medication requirements within the study,

          -  Ability to understand the goal and risks of this study.

        Exclusion Criteria:

          -  Intracranial aneurysm considered not suitable for FD using p64 MW HPC or p48 MW HPC.

          -  Aneurysm previously treated with a device in the parent vessel (e.g., stent, flow
             diverter).

          -  Another intracranial procedure scheduled for the following 6 months.

          -  Age &lt; 18 years and &gt; 80 years.

          -  Pregnancy possible or confirmed. Patient not able or willing to arrange contraception
             for 12 months after treatment.

          -  Patient not able or willing to adhere to the study protocol.

          -  Patient not able or willing to undergo the scheduled follow-up examinations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hans Henkes, Prof. Dr.</last_name>
    <phone>+49 711 27834501</phone>
    <email>h.henkes@klinikum-stuttgart.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrey Petrov, Dr.</last_name>
    <email>doctorpetrovandrey@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shastin Central Hospital</name>
      <address>
        <city>Ulaanbaatar</city>
        <state>Bayangol District</state>
        <zip>10th khoroolol-2</zip>
        <country>Mongolia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganbaatar Rentsenkhuu, Dr.</last_name>
      <email>ganbaatar.neuro@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ganbaatar Rentsenkhuu, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mongolia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>p64 MW HPC</keyword>
  <keyword>p48 MW HPC</keyword>
  <keyword>Flow Diverter</keyword>
  <keyword>HPC</keyword>
  <keyword>Dual antiplatelet therapy</keyword>
  <keyword>Outcome</keyword>
  <keyword>Occlusion</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

